Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance

Human Immunology

Volumn 75, Issue 4, 2014, Pages 330-337

  Gaur, Poonam ^a   Singh, Avadhesh Kumar ^a   Shukla, Nootan K ^b   Das, Satya N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; RISK; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS; TUMOR BURDEN;

EID: 84895560831     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.01.011     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers D, Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC cancer base No. 10 (Lyon, France: International agency for research on cancer, 2010). available from: 2013 [accessed 25.04.13]. http://globocan.iarc.fr.
2. Müller-Hübenthal B., Azemar M., Lorenzen D., Huber M., Freudenberg M.A., Galanos C., et al. Tumour biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res 2009, 29:4795-4805.
3. Song B.-C., Chung Y.-H., Kim J.A., Choi W.-B., Suh D.D., Pyo S.I., et al. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002, 94:175-180.
4. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004, 101:2727-2736.
5. Hathaway B., Landsittel D.P., Gooding W., Whiteside T.L., Grandis J.R., Siegfried J.M., et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 2005, 115:522-527.
6. Nacinović-Duletić A., Stifter S., Dvornik S., Skunca Z., Jonjić N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 2008, 30:230-239.
7. Wu J., Du J., Liu L., Li Q., Rong W., Wang L., et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One 2012, 7:e50035.
8. St John M.A., Li Y., Zhou X., Denny P., Ho C.-M., Montemagno C., et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004, 130:929-935.
9. Kenneth Murphy Cytokines. Garland Sciences 2012, Taylor and Francis group, LLC, London and New York.
10. Taga K., Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992, 148:1143-1148.
11. Yue F.Y., Dummer R., Geertsen R., Hofbauer G., Laine E., Manolio S., et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997, 71:630-637.
12. De Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
13. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991, 174:1549-1555.
14. Wrzesinski S.H., Wan Y.Y., Flavell R.A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007, 13:5262-5270.
15. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006, 25:435-457.
16. Murugaiyan G., Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009, 183:4169-4175.
17. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008, 14:3254-3261.
18. Koyama K., Kagamu H., Miura S., Hiura T., Miyabayashi T., Itoh R., et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008, 14:6770-6779.
19. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
20. Wägsäter D., Löfgren S., Hugander A., Dimberg J. Expression of interleukin-17 in human colorectal cancer. Anticancer Res 2006, 26:4213-4216.
21. Zhang B., Rong G., Wei H., Zhang M., Bi J., Ma L., et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008, 374:533-537.
22. Gaur P., Qadir G.A., Upadhyay S., Singh A.K., Shukla N.K., Das S.N. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr) 2012, 35:335-343.
23. Zhou L., Lopes J.E., Chong M.M.W., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
24. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
25. + regulatory T cells in humans. Proc Natl Acad Sci USA 2009, 106:4793-4798.
26. Chen M.F., Wang W.H., Lin P.Y., Lee K.D., Chen W.C. Significance of the TGF-β1/IL-6 axis in oral cancer. Clin Sci (Lond) 2012, 122:459-472.
27. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
28. H17 responses in a Stat3-dependent manner. Science 2009, 326:986-991.
29. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
30. Meng X.Y., Zhou C.H., Ma J., Jiang C., Ji P. Expression of interleukin-17 and its clinical significance in gastric cancer patients. Med Oncol 2012, 29:3024-3028.
31. Lemancewicz D., Bolkun L., Jablonska E., Czeczuga-Semeniuk E., Kostur A., Kloczko J., et al. The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients. Med Sci Monit 2012, 18:BR54-BR59.
32. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995, 1:282-284.
33. Sheen-Chen S.M., Chen H.S., Sheen C.W., Eng H.L., Chen W.J. Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 2001, 136:937-940.
34. Shim K.S., Kim K.H., Han W.S., Park E.B. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999, 85:554-561.
35. Sharma A., Khan R., Joshi S., Kumar L., Sharma M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010, 51:920-927.
36. Inagaki A., Ishida T., Ishii T., Komatsu H., Iida S., Ding J., et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006, 118:3054-3061.
37. Ogawara H., Handa H., Yamazaki T., Toda T., Yoshida K., Nishimoto N., et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005, 29:135-140.
38. Agarwal A., Rani M., Saha G.K., Valarmathi T.M., Bahadur S., Mohanti B.K., et al. Dys-regulated expression of TH2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003, 32:17-30.
39. Manchanda P., Sharma S.C., Das S.N. Differential regulation of IL-2 and IL-4 in patients with tobacco related oral squamous cell carcinoma. Oral Dis 2006, 12:455-462.
40. Dwivedi S., Goel A., Natu S.M., Mandhani A., Khattri S., Pant K.K. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev 2011, 12:1843-1848.
41. Enewold L., Mechanic L.E., Bowman E.D., Zheng Y.-L., Yu Z., Trivers G., et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009, 18:215-222.
42. Lech-Maranda E., Bienvenu J., Michallet A.-S., Houot R., Robak T., Coiffier B., et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 2006, 17:60-66.
43. Guney N., Soydinc H.O., Basaran M., Bavbek S., Derin D., Camlica H., et al. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 2009, 10:669-674.
44. Xiong B., Yuan H.-Y., Hu M.-B., Zhang F., Wei Z.-Z., Gong L.-L., et al. Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J Gastroenterol 2002, 8:674-678.
45. Gaur P., Mittal M., Mohanti B.K., Das S.N. Functional variants of IL4 and IL6 genes and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Dis 2011, 17:720-726.
46. Gaur P., Mittal M., Mohanti B.K., Das S.N. Functional genetic variants of TGF-β1 and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Oral Oncol 2011, 14:1117-1121.